Crystal structures of complexes of a peptidic inhibitor with wild-type and two mutant HIV-1 proteases

被引:50
作者
Hong, L
Treharne, A
Hartsuck, JA
Foundling, S
Tang, J
机构
[1] OKLAHOMA MED RES FDN,PROT STUDIES PROGRAM,OKLAHOMA CITY,OK 73104
[2] UNIV OKLAHOMA,HLTH SCI CTR,DEPT BIOCHEM & MOL BIOL,OKLAHOMA CITY,OK 73104
关键词
D O I
10.1021/bi960481s
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Crystal structures of the protease of human immunodeficiency virus type 1 (HIV-1) and two mutant proteases, V82D and V82N, have been determined. In all three cases the enzyme forms a complex with the peptidic inhibitor U-89360E. All structures have been determined to 2.3 Angstrom resolution and have satisfactory agreement factors: 0.173 for wild type, 0.175 for V82D, and 0.182 for V82N. Comparison of the three crystal structures provides explanations which are consistent with the known kinetic properties of these mutant enzymes with the U-89360E inhibitor [Lin, Y., Lin, X., Hong, L., Foundling, S., Heinrikson, R. L., Thaisrivongs, S., Leelamanit, W., Raterman, D., Shah, M., Dunn, B. M., & Tang, J. (1995) Biochemistry 34, 1143-1152]. Unfavorable van der Waals interactions between the inhibitor and the mutated side chains at position 82 are consistent with diminished affinity for the inhibitor by the mutant enzymes. If a mutation is potentially resistant to an inhibitor, the mutant enzyme should not only have an increased K-i for the inhibitor but should also preserve considerable catalytic capability. The V82D mutant possesses these qualities. In the V82D crystal structure, a water molecule, which connects the protease flap to the inhibitor, is missing or of low occupancy. Absence of this bridge may be important in determining catalytic capability. Moreover, mutation at position 82 induces change in two polypeptide backbone regions, 35-41 and 67-68, which may be related to protease flap mobility.
引用
收藏
页码:10627 / 10633
页数:7
相关论文
共 38 条
[11]   THE NOT-SO-GREAT ESCAPE [J].
ERICKSON, JW .
NATURE STRUCTURAL BIOLOGY, 1995, 2 (07) :523-529
[12]  
FITZGERALD PMD, 1990, J BIOL CHEM, V265, P14209
[13]   KINETIC CHARACTERIZATION AND CROSS-RESISTANCE PATTERNS OF HIV-1 PROTEASE MUTANTS SELECTED UNDER DRUG PRESSURE [J].
GULNIK, SV ;
SUVOROV, LI ;
LIU, BS ;
YU, B ;
ANDERSON, B ;
MITSUYA, H ;
ERICKSON, JW .
BIOCHEMISTRY, 1995, 34 (29) :9282-9287
[14]   DOMAIN COMMUNICATION IN THE DYNAMIC STRUCTURE OF HUMAN IMMUNODEFICIENCY VIRUS-1 PROTEASE [J].
HARTE, WE ;
SWAMINATHAN, S ;
MANSURI, MM ;
MARTIN, JC ;
ROSENBERG, IE ;
BEVERIDGE, DL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (22) :8864-8868
[15]   RAPID TURNOVER OF PLASMA VIRIONS AND CD4 LYMPHOCYTES IN HIV-1 INFECTION [J].
HO, DD ;
NEUMANN, AU ;
PERELSON, AS ;
CHEN, W ;
LEONARD, JM ;
MARKOWITZ, M .
NATURE, 1995, 373 (6510) :123-126
[16]   HIV PROTEASE - A NOVEL CHEMOTHERAPEUTIC TARGET FOR AIDS [J].
HUFF, JR .
JOURNAL OF MEDICINAL CHEMISTRY, 1991, 34 (08) :2305-2314
[17]  
IDO E, 1991, J BIOL CHEM, V266, P24359
[18]   GRAPHICS MODEL-BUILDING AND REFINEMENT SYSTEM FOR MACROMOLECULES [J].
JONES, TA .
JOURNAL OF APPLIED CRYSTALLOGRAPHY, 1978, 11 (AUG) :268-272
[19]   IMPROVED METHODS FOR BUILDING PROTEIN MODELS IN ELECTRON-DENSITY MAPS AND THE LOCATION OF ERRORS IN THESE MODELS [J].
JONES, TA ;
ZOU, JY ;
COWAN, SW ;
KJELDGAARD, M .
ACTA CRYSTALLOGRAPHICA SECTION A, 1991, 47 :110-119
[20]   STRUCTURE-BASED, C2 SYMMETRICAL INHIBITORS OF HIV PROTEASE [J].
KEMPF, DJ ;
NORBECK, DW ;
CODACOVI, LM ;
WANG, XC ;
KOHLBRENNER, WE ;
WIDEBURG, NE ;
PAUL, DA ;
KNIGGE, MF ;
VASAVANONDA, S ;
CRAIGKENNARD, A ;
SALDIVAR, A ;
ROSENBROOK, W ;
CLEMENT, JJ ;
PLATTNER, JJ ;
ERICKSON, J .
JOURNAL OF MEDICINAL CHEMISTRY, 1990, 33 (10) :2687-2689